ArticleInternational journal of clinical and experimental pathology2019
miR-423-5p inhibits the proliferation and metastasis of glioblastoma cells by targeting phospholipase C beta 1.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- LncRNA AC100826.1 regulated PLCB1 to promote progression in non-small cell lung cancer.Thoracic cancer · 2024Article
- Article
- A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes.Clinical epigenetics · 2023Article
- CXCL14 promotes metastasis of non-small cell lung cancer through ACKR2-depended signaling pathway.International journal of biological sciences · 2023Article
- Circ_FURIN knockdown assuages Testosterone-induced human ovarian granulosa-like tumor cell disorders by sponging miR-423-5p to reduce MTM1 expression in polycystic ovary syndrome.Reproductive biology and endocrinology : RB&E · 2022Article
- MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer.Journal of experimental & clinical cancer research : CR · 2022Article
- Genetic Variation in MicroRNA-423 Promotes Proliferation, Migration, Invasion, and Chemoresistance in Breast Cancer Cells.International journal of molecular sciences · 2021Article
- Article
- Functional mechanism and clinical implications of MicroRNA-423 in human cancers.Cancer medicine · 2020Review
- Functional Analysis of the 3' Untranslated Region of the HumanNeuropsychiatric disease and treatment · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is a common brain tumor which is highly invasive, responds poorly to therapy, and has a poor prognosis. There is growing evidence that an abnormal expression of many genes is related to glioma and leads to glioma cell growth and metastasis. Phospholipase C beta 1 (PLCB1) plays critical roles in intracellular transduction and regulating signal activation, which are important to tumorigenesis. Therefore, it could bind to miRNA as a target gene. The purpose of our study was to confirm that PLCB1 plays a critical role in suppressing glioma progression. We found that the expression of miR-423-5p was reduced, but the expression of PLCB1 was increased, in glioma tissues and cells. To explore whether miR-423-5p affects PLCB1, a bioinformatics approach suggested that miR-423-5p can directly target PLCB1. Moreover, we observed, using luciferase reporter assays, that miR-423-5p could target PLCB1 3'-UTR. Functionally, the overexpression of miR-423-5p could attenuate the proliferation, invasion, and migration and promote the apoptosis of glioma cells. Furthermore, we found that miR-423-5p could enhance p-ERK expression in glioma cells. Taken together, we deduced that miR-423-5p inhibited proliferation and metastasis by targeting PLCB1, and it also promotes apoptosis in glioma cells. These results suggest that miR-423-5p directly targets PLCB1 3'-UTR and could inhibit cell invasion and migration through the ERK-dependent pathway in glioma, and the miR-423-5p/PLCB1 axis may be a potential target for new potential therapeutic strategies to treat glioma.
Indexed as
Identifiers
31934130PMC6949730W3026824030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.